Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pembrolizumab · 1 trial · 1 indication
The proportion of patients having either a complete response (CR) or partial response (PR), per RECIST 1.1. Complete Response (CR): Disappearance of all target lesions. For non-target lesions, CR is the disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.
| Arm | Type | Description |
|---|---|---|
| ALX148 + Doxorubicin (PLD) + Pembrolizumab | EXPERIMENTAL | Given on Day 1 of each 21 day cycle, in the following order of administration: 200 mg IV pembrolizumab\* (maximum of 2 years (approximately 35 cycles) 45 mg/kg IV ALX148 30 mg/m\^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)\* \*standard of care |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab | DRUG | A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells. |
| ALX148 | DRUG | A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer. |
| Doxorubicin | DRUG | An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer. |
Inclusion Criteria: 1. Participants must have recurrent epithelial ovarian cancer. 2. Platinum-resistant disease: Patients who recur within \< 6 months of prior platinum-based therapy excluding those with primary platinum refractory disease (see exclusion criteria). 3. Following histology types are...
Top 20 of 59 competitors
Pembrolizumab is being studied in combination with ALX148 and liposomal doxorubicin for the treatment of recurrent platinum-resistant ovarian cancer. It is currently in Phase 2 clinical development for this indication.
Pembrolizumab is an antibody that targets the PD-1 receptor, a protein on immune cells that helps regulate immune responses. By blocking PD-1, it aims to enhance the body's immune attack against cancer cells.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is developing Pembrolizumab in combination with ALX148 and liposomal doxorubicin for recurrent platinum-resistant ovarian cancer. The company is conducting a Phase 2 clinical trial for this combination.
Pembrolizumab is in Phase 2 clinical development for recurrent platinum-resistant ovarian cancer. It is being tested in combination with ALX148 and liposomal doxorubicin in an ongoing clinical trial.
Pembrolizumab is being studied in the clinical trial NCT05467670, titled 'Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer.' This Phase 2 trial is active but not recruiting, with an enrollment of 16 participants.
No, Pembrolizumab and ALX148 are different drugs. Pembrolizumab is an antibody targeting PD-1, while ALX148 is an anti-CD47 agent. They are being studied together in combination with liposomal doxorubicin for ovarian cancer.